Panel review of anaplastic oligodendroglioma from European organization for research and treatment of cancer trial 26951: Assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome

Johan M. Kros, Thierry Gorlia, Mathilde C. Kouwenhoven, Ping P. Zheng, V. Peter Collins, Dominique Figarella-Branger, Felice Giangaspero, Caterina Giannini, Karima Mokhtari, Sverre J. Mørk, Anders Paetau, Guido Reifenberger, Martin J. Van Den Bent

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

The diagnosis of anaplastic oligodendroglioma (AOD) or anaplastic oligoastrocytoma (AOA) is subject to interobserver variation. The aim of this study was to estimate consensus in typing and grading of these tumors using tumor material collected in a large prospective randomized phase III study and to correlate the consensus diagnosis with the 1p/19q status of the tumors and the clinical outcome. The available pathology material of the first 150 patients, randomized into the European Organization for Research and Treatment of Cancer Trial 26951, was reviewed by an independent panel of 9 neuropathologists. The presence of deletions of 1p and 19q was assessed by fluorescence in situ hybridization with locus-specific probes. The panel reached consensus on the diagnosis of AOD in 52% of the tumors that had been diagnosed as AOD by the local pathologists, whereas only 8% of the local diagnosis of AOA was confirmed with consensus. The concordance on the panel diagnosis of AOD was high (intraclass correlation = 86%). The survival curves for AOD with 1p/19q loss, AOD without these losses, and AOA without 1p/19q loss ran separately in this order. The absence of necrosis and the presence of endothelial abnormalities were correlated with better outcomes. In multivariate analysis, patients' age, 1p/19q loss, and necrosis were identified as independent prognostic factors.

Original languageEnglish (US)
Pages (from-to)545-551
Number of pages7
JournalJournal of Neuropathology and Experimental Neurology
Volume66
Issue number6
DOIs
StatePublished - Jun 2007

Fingerprint

Oligodendroglioma
Research
Neoplasms
Necrosis
Therapeutics
Observer Variation
Neoplasm Grading
Fluorescence In Situ Hybridization
Multivariate Analysis
Pathology
Survival

Keywords

  • 19q loss
  • 1p loss
  • Chromosomal aberration
  • Glioma
  • Histopathology
  • Oligodendroglioma
  • Phase III trial

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Neuroscience(all)

Cite this

Panel review of anaplastic oligodendroglioma from European organization for research and treatment of cancer trial 26951 : Assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. / Kros, Johan M.; Gorlia, Thierry; Kouwenhoven, Mathilde C.; Zheng, Ping P.; Collins, V. Peter; Figarella-Branger, Dominique; Giangaspero, Felice; Giannini, Caterina; Mokhtari, Karima; Mørk, Sverre J.; Paetau, Anders; Reifenberger, Guido; Van Den Bent, Martin J.

In: Journal of Neuropathology and Experimental Neurology, Vol. 66, No. 6, 06.2007, p. 545-551.

Research output: Contribution to journalArticle

Kros, Johan M. ; Gorlia, Thierry ; Kouwenhoven, Mathilde C. ; Zheng, Ping P. ; Collins, V. Peter ; Figarella-Branger, Dominique ; Giangaspero, Felice ; Giannini, Caterina ; Mokhtari, Karima ; Mørk, Sverre J. ; Paetau, Anders ; Reifenberger, Guido ; Van Den Bent, Martin J. / Panel review of anaplastic oligodendroglioma from European organization for research and treatment of cancer trial 26951 : Assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. In: Journal of Neuropathology and Experimental Neurology. 2007 ; Vol. 66, No. 6. pp. 545-551.
@article{2d82652c69df4b459db4dc83e5b2ba3e,
title = "Panel review of anaplastic oligodendroglioma from European organization for research and treatment of cancer trial 26951: Assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome",
abstract = "The diagnosis of anaplastic oligodendroglioma (AOD) or anaplastic oligoastrocytoma (AOA) is subject to interobserver variation. The aim of this study was to estimate consensus in typing and grading of these tumors using tumor material collected in a large prospective randomized phase III study and to correlate the consensus diagnosis with the 1p/19q status of the tumors and the clinical outcome. The available pathology material of the first 150 patients, randomized into the European Organization for Research and Treatment of Cancer Trial 26951, was reviewed by an independent panel of 9 neuropathologists. The presence of deletions of 1p and 19q was assessed by fluorescence in situ hybridization with locus-specific probes. The panel reached consensus on the diagnosis of AOD in 52{\%} of the tumors that had been diagnosed as AOD by the local pathologists, whereas only 8{\%} of the local diagnosis of AOA was confirmed with consensus. The concordance on the panel diagnosis of AOD was high (intraclass correlation = 86{\%}). The survival curves for AOD with 1p/19q loss, AOD without these losses, and AOA without 1p/19q loss ran separately in this order. The absence of necrosis and the presence of endothelial abnormalities were correlated with better outcomes. In multivariate analysis, patients' age, 1p/19q loss, and necrosis were identified as independent prognostic factors.",
keywords = "19q loss, 1p loss, Chromosomal aberration, Glioma, Histopathology, Oligodendroglioma, Phase III trial",
author = "Kros, {Johan M.} and Thierry Gorlia and Kouwenhoven, {Mathilde C.} and Zheng, {Ping P.} and Collins, {V. Peter} and Dominique Figarella-Branger and Felice Giangaspero and Caterina Giannini and Karima Mokhtari and M{\o}rk, {Sverre J.} and Anders Paetau and Guido Reifenberger and {Van Den Bent}, {Martin J.}",
year = "2007",
month = "6",
doi = "10.1097/01.jnen.0000263869.84188.72",
language = "English (US)",
volume = "66",
pages = "545--551",
journal = "American Journal of Psychotherapy",
issn = "0002-9564",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Panel review of anaplastic oligodendroglioma from European organization for research and treatment of cancer trial 26951

T2 - Assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome

AU - Kros, Johan M.

AU - Gorlia, Thierry

AU - Kouwenhoven, Mathilde C.

AU - Zheng, Ping P.

AU - Collins, V. Peter

AU - Figarella-Branger, Dominique

AU - Giangaspero, Felice

AU - Giannini, Caterina

AU - Mokhtari, Karima

AU - Mørk, Sverre J.

AU - Paetau, Anders

AU - Reifenberger, Guido

AU - Van Den Bent, Martin J.

PY - 2007/6

Y1 - 2007/6

N2 - The diagnosis of anaplastic oligodendroglioma (AOD) or anaplastic oligoastrocytoma (AOA) is subject to interobserver variation. The aim of this study was to estimate consensus in typing and grading of these tumors using tumor material collected in a large prospective randomized phase III study and to correlate the consensus diagnosis with the 1p/19q status of the tumors and the clinical outcome. The available pathology material of the first 150 patients, randomized into the European Organization for Research and Treatment of Cancer Trial 26951, was reviewed by an independent panel of 9 neuropathologists. The presence of deletions of 1p and 19q was assessed by fluorescence in situ hybridization with locus-specific probes. The panel reached consensus on the diagnosis of AOD in 52% of the tumors that had been diagnosed as AOD by the local pathologists, whereas only 8% of the local diagnosis of AOA was confirmed with consensus. The concordance on the panel diagnosis of AOD was high (intraclass correlation = 86%). The survival curves for AOD with 1p/19q loss, AOD without these losses, and AOA without 1p/19q loss ran separately in this order. The absence of necrosis and the presence of endothelial abnormalities were correlated with better outcomes. In multivariate analysis, patients' age, 1p/19q loss, and necrosis were identified as independent prognostic factors.

AB - The diagnosis of anaplastic oligodendroglioma (AOD) or anaplastic oligoastrocytoma (AOA) is subject to interobserver variation. The aim of this study was to estimate consensus in typing and grading of these tumors using tumor material collected in a large prospective randomized phase III study and to correlate the consensus diagnosis with the 1p/19q status of the tumors and the clinical outcome. The available pathology material of the first 150 patients, randomized into the European Organization for Research and Treatment of Cancer Trial 26951, was reviewed by an independent panel of 9 neuropathologists. The presence of deletions of 1p and 19q was assessed by fluorescence in situ hybridization with locus-specific probes. The panel reached consensus on the diagnosis of AOD in 52% of the tumors that had been diagnosed as AOD by the local pathologists, whereas only 8% of the local diagnosis of AOA was confirmed with consensus. The concordance on the panel diagnosis of AOD was high (intraclass correlation = 86%). The survival curves for AOD with 1p/19q loss, AOD without these losses, and AOA without 1p/19q loss ran separately in this order. The absence of necrosis and the presence of endothelial abnormalities were correlated with better outcomes. In multivariate analysis, patients' age, 1p/19q loss, and necrosis were identified as independent prognostic factors.

KW - 19q loss

KW - 1p loss

KW - Chromosomal aberration

KW - Glioma

KW - Histopathology

KW - Oligodendroglioma

KW - Phase III trial

UR - http://www.scopus.com/inward/record.url?scp=34249915554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249915554&partnerID=8YFLogxK

U2 - 10.1097/01.jnen.0000263869.84188.72

DO - 10.1097/01.jnen.0000263869.84188.72

M3 - Article

C2 - 17549014

AN - SCOPUS:34249915554

VL - 66

SP - 545

EP - 551

JO - American Journal of Psychotherapy

JF - American Journal of Psychotherapy

SN - 0002-9564

IS - 6

ER -